Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034

Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034

Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Endometriosis market through 2034.

GlobalData estimates the 2024 sales for the endometriosis market at approximately $938.0 million across the 7MM, encompassing the US, the 5EU, and Japan. By 2034, GlobalData expects the overall market to grow at a compound annual growth rate (CAGR) of 10.3% to reach sales of $2.5 billion over the 10-year period. The US market will grow fastest, with a 13.2% CAGR, compared to a decline of 0.7% in the 5EU and growth of 1.0% in Japan. At the end of 2034, the US will contribute approximately 88.4% of global sales. The higher sales in the US relative to the other two regions can be attributed to the greater diagnosed prevalence of endometriosis in the US and the higher price of drugs in the US compared to other global markets.

Major drivers of the endometriosis market during the forecast period will include -

• The launch of Kissei Pharmaceutical’s Yselty (linzagolix), which is currently marketed in the in the US and Japan
• The launch of Hope Medicine’s HMI-115 in the US and Fuji Pharma’s Alyssa (drospirenone + estetrol) in Japan
• Continual improvements with disease awareness, leading to an increase in diagnoses
• Improvements in non-invasive diagnostic methods, such as the utilization of biomarkers, which should further increase the number of early diagnoses

Major barriers to the growth of the endometriosis market during the forecast period are as follows -

• The endometriosis market boasts many off-label medications and is still highly genericized, presenting a stiff barrier for novel therapy entrants.
• The shrinking female population ages 12–54 years in the 5EU and Japan will dampen the extent of growth in diagnosed endometriosis cases.

Scope

• Overview of endometriosis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized endometriosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the endometriosis therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for endometriosis treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global endometriosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM endometriosis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM endometriosis therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note: this is delivered as a Zip file.